Effect of Administration of 3rd Generation Cephalosporin on the Digestive Carrying of 3rd Generation Cephalosporin-resistant Enterobacteriaceae (CEF-IMPACT)

Centre Hospitalier Universitaire de Besancon250 enrolled

Overview

The aim of this study was to compare the frequency of occurrence of digestive carrying of 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R), acquired during hospitalization in one of the participating departments, between patients treated with ceftriaxone and patients treated with cefotaxime

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

250

Conditions

Infectious Disease - Resistant Enterobacteriaceae (Diagnosis)

Interventions

Cefotaxime InjectionDRUG

Systematic use of cefotaxime.

Rectal swabPROCEDURE

Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion

Cefotaxime/ceftriaxoneDRUG

ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years old * Indication for antibiotic treatment with a 3rd generation injectable cephalosporin (cefotaxime or ceftriaxone) * Signed Informed Consent Exclusion Criteria: * Hypersensitivity to ceftriaxone or cefotaxime, to another cephalosporin or to any of the excipients of the specialities concerned. * History of severe hypersensitivity (e.g., anaphylactic reaction) to another class of antibacterial agent of the beta-lactam family (penicillins, monobactams and carbapenes) * Subcutaneous administration of ceftriaxone * Pregnant and breastfeeding woman * Suspicion of Pseudomonas infection or documented Pseudomonas infection requiring ceftazidime treatment * Suspicion of group III enterobacteriaceae infection or group III enterobacteriaceae infection requiring cefepime treatment

Locations (1)

CHU de Besançon

Besançon, France

RECRUITING

Outcomes

Primary Outcomes

Frequency of occurrence of digestive carrying of EB C3G-R

Time frame: 30 days after inclusion

Secondary Outcomes

incidence rate of EB C3G-R infections

Evaluate the effect of systematic use of cefotaxime rather than ceftriaxone on the incidence rate of EB C3G-R infections in participating departments.

Time frame: 2 years

number of patients with occurrence of positive rectal swab with 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R)

Compare the number of patients with occurrence of positive rectal swab with 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R), 30 days after inclusion, between patients treated with ceftriaxone and patients treated with cefotaxime.

Time frame: 30 days after inclusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.